Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Shouwa-ku, Nagoya 466-8550, Japan.
Hum Pathol. 2010 Apr;41(4):560-5. doi: 10.1016/j.humpath.2009.09.010. Epub 2009 Dec 11.
Tthyroid transcription factor 1 is a marker of lung and thyroid carcinomas, but thyroid transcription factor 1 immunoreactivity is seen in other malignancies. We examined the incidence of thyroid transcription factor 1 expression in gynecologic tumors in Japanese patients, and we further evaluated the presence of epidermal growth factor receptor mutations in thyroid transcription factor 1-positive gynecologic malignancies. A total of 186 patient samples collected at our hospitals between 1991 and 2006 were analyzed, and these specimens consisted of 83 ovarian carcinomas, 55 endometrioid endometrial adenocarcinomas of the uterus, 28 cervical adenocarcinomas of the uterus, and 20 leiomyosarcomas of the uterus. Thyroid transcription factor 1 expression was assessed by immunohistochemistry. The presence of epidermal growth factor receptor mutations was investigated by polymerase chain reaction analyses. Thyroid transcription factor 1 was detected in the nuclei of 11 ovarian carcinomas (13%) and 5 endometrioid adenocarcinomas (10%) of the uterus. In patients with ovarian carcinoma, thyroid transcription factor 1 staining was associated with significantly improved progression-free (P = .017) and overall survival (P = .017) using univariate analysis. Multivariate analysis identified thyroid transcription factor 1 expression as an independent prognostic factor for ovarian cancer (P = .0467). No epidermal growth factor receptor mutations were found in our study. Thyroid transcription factor 1 is expressed with relatively low frequencies in gynecologic malignancies, but thyroid transcription factor 1 expression confers a better prognosis in patients with ovarian cancer. No epidermal growth factor receptor mutations were found in the thyroid transcription factor 1-positive gynecologic malignancies, and we were unable to establish a relationship between epidermal growth factor receptor mutations and thyroid transcription factor 1 immunopositivity, as was previously shown for lung cancer.
甲状腺转录因子 1 是肺癌和甲状腺癌的标志物，但甲状腺转录因子 1 免疫反应性也可见于其他恶性肿瘤。我们检测了甲状腺转录因子 1 在日本患者妇科肿瘤中的表达，进一步评估了甲状腺转录因子 1 阳性妇科恶性肿瘤中表皮生长因子受体突变的存在。我们分析了 1991 年至 2006 年期间在我院收集的 186 例患者样本，这些标本包括 83 例卵巢癌、55 例子宫内膜腺癌、28 例子宫颈腺癌和 20 例子宫平滑肌肉瘤。通过免疫组织化学评估甲状腺转录因子 1 的表达。通过聚合酶链反应分析研究表皮生长因子受体突变的存在。甲状腺转录因子 1 在 11 例卵巢癌（13%）和 5 例子宫内膜腺癌（10%）的细胞核中被检测到。在卵巢癌患者中，甲状腺转录因子 1 染色与无进展生存（P =.017）和总生存（P =.017）显著相关，这是单因素分析的结果。多因素分析确定甲状腺转录因子 1 表达是卵巢癌的独立预后因素（P =.0467）。在我们的研究中未发现表皮生长因子受体突变。甲状腺转录因子 1 在妇科恶性肿瘤中的表达频率相对较低，但甲状腺转录因子 1 表达可使卵巢癌患者的预后更好。在甲状腺转录因子 1 阳性的妇科恶性肿瘤中未发现表皮生长因子受体突变，并且我们无法建立表皮生长因子受体突变与甲状腺转录因子 1 免疫阳性之间的关系，正如先前在肺癌中所示。
